Mergers & Acquisitions ·
Windtree Therapeutics signed an agreement on December 16, 2025, to sell its cardiovascular drug candidates to Seismic…
WINTWindtree Therapeutics Inc
Windtree Therapeutics signed an agreement on December 16, 2025, to sell its cardiovascular drug candidates to Seismic Pharmaceutical Operations, LLC. The transaction includes a $150,000 closing cash payment, the transfer of cardiovascular development payables to the buyer, and a contingent payment of $700,000 if the buyer completes a financing round of at least $10 million. Windtree retains a right to 20% of any future milestone payments, royalty payments, or global commercial net revenues from the assets. The company operates in the biotechnology industry and develops drug candidates for various medical conditions.